Psoriatic Arthritis

Upadacitinib demonstrates comparable efficacy and safety as monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs in patients with psoriatic arthritis, according to data published in Rheumatology.

Patients with self-reported elevated spine symptoms in psoriatic arthritis, with or without a diagnosis of axial disease, had worse quality of life and disease activity overall versus patients without axial manifestations, according to data.

The FDA has approved Rinvoq, a 15-mg, once-daily oral JAK inhibitor, for the treatment of adults with active psoriatic arthritis who have had an inadequate response, or intolerance to, TNF inhibitors, according to an AbbVie press release.

Recent data found that dermatomyositis was more prevalent than had been thought. The retrospective, population-based cohort study that led to this conclusion was the top story in rheumatology last week.

Guselkumab is associated with durable improvements in multiple psoriatic disease domains through 2 years, with no new safety findings, in patents who are biologic-naïve, according to data published in Arthritis & Rheumatology.

A university psoriatic arthritis center focusing on close collaboration between rheumatologists and dermatologists helped significantly decrease time to diagnosis, according to data published in BMC Rheumatology.

Topline phase 3 study results found bimekizumab superior to placebo in improving signs and symptoms of psoriatic arthritis, UCB announced in a press release.

Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis, resulting in a significantly longer time to flare versus placebo, according to data presented at ACR Convergence 2021.

While there is a cross-section of drugs that are FDA-approved for the treatment of axial spondyloarthritis, clinicians and researchers continue to struggle with axial psoriatic arthritis, according to a presenter at ACR Convergence 2021.

Hospitalizations for sepsis, skin and soft tissue infections and UTI among patients with psoriatic arthritis “significantly” decreased over a 5-year period despite a rising uptake in biologics, according to data presented at ACR Convergence 2021.